Eligard
Manufacturing · Illinois, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
485 E Half Day Rd Ste 400, Buffalo Grove...Phone Number
(224) 880-5770Website
www.eligard.comRevenue
$5.3 MillionIndustry
About Eligard
Is Eligard your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Eligard launches new products
Congratulate Masked Content for being promoted to Masked Content at Eligard
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Eligard recently announced quarterly report
Eligard, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Eligard has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Eligard has new funding data
Check out if Eligard is spiking on competitors!
Click to see if Eligard had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Eligard as Masked Content
Find more new buyers
Compare Similar Companies to Eligard
Compare insights from companies similar to Eligard, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Eligard
Company Profile Activity
Activity Insights
Eligard is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eligard is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eligard.
Eligard Tech Stack
A closer look at the technologies used by Eligard
Eligard News & Media
Data on Nadir Testosterone Levels Achieved by ELIGARD® (leuprolide acetate) for injectable suspension published in Reviews in Urology
CHICAGO, July 24, 2019 (GLOBE NEWSWIRE) -- Tolmar Pharmaceuticals, Inc. today announced the publication of a study of nadir testosterone (T) levels achieved in pivotal trials for ELIGARD® (leuprolide acetate) for injectable suspension. The study, published in Reviews in Urology, was the first to evaluate nadir serum T in patients treated with a luteinizing hormone-releasing hormone (LHRH) agonist, in this case subcutaneous leuprolide acetate. Nadir serum testosterone, or “nadir T,” is the lELIGARD® (Leuprolide Acetate) for Injectable Suspension Continues Growth Momentum With Securing Favorable Formulary Position as the Lowest WAC Priced, and Only Subcutaneously Administered Leuprolide Acetate for the Palliative Treatment of Advanced Prostate Cancer
Formulary Placement with EnvisionRx Fuels Market-Leading Growth Formulary Placement with EnvisionRx Fuels Market-Leading GrowthTolmar Pharmaceuticals Sponsors 2018 ZERO - The End of Prostate Cancer Endurance Team at the Bank of America Chicago Marathon
CHICAGO and BOSTON, Oct. 5, 2018 /PRNewswire/ -- Tolmar Pharmaceuticals, Inc. today announced its exclusive sponsorship of ZERO - The End of Prostate Cancer's (ZERO) Endurance Team at the 2018 Bank of America Chicago Marathon. ZERO is the leading national nonprofit organization dedicated...
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eligard
Official Web site for ELIGARD, a palliative treatment for advanced prostate cancer. Please see Important Safety Information.... Read More